Amgen says Aranesp may decrease mortality in heart-failure patients with anemia

By Elaine Rigoli

Tampa, Fla., June 19 - Amgen Inc. announced results from a phase 2 study showing that, in patients with symptomatic heart failure and anemia, Aranesp (darbepoetin alfa) was well tolerated and effectively raised hemoglobin.

Amgen also announced results from a prespecified pooled analysis including these data and previously released data from a second phase 2 study, showing that treatment with Aranesp may decrease the risk of heart failure hospitalization and all-cause mortality, and improve symptoms.

These results require confirmation from a large phase 3 randomized controlled clinical trial, the company said in a news release.

Amgen, located in Thousand Oaks, Calif., develops human therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.